^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DF1001

    i
    Other names: DF1001, DF 1001
    Company:
    Dragonfly Therap
    Drug class:
    HER2 inhibitor
    Related drugs:
    3ms
    Study of DF1001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2; Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jul 2025 --> Oct 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 positive • EGFR mutation • HR positive • HER-2 mutation • HER-2 expression • RET mutation
    |
    HercepTest
    |
    Opdivo (nivolumab) • albumin-bound paclitaxel • Trodelvy (sacituzumab govitecan-hziy) • DF1001
    1year
    Phase 1/2 Study of DF1001, a novel tri-specific, NK cell engager therapy targeting HER2, in patients with advanced solid tumors: Phase 1 DF1001 monotherapy dose-escalation results. (ASCO 2023)
    In this dose escalation study, DF1001 is shown to be a safe and well-tolerated novel NK cell engager therapy targeting HER2. DF1001 monotherapy demonstrates promising anti-tumor activity in treatment refractory patients with a spectrum of HER2 expression as well as MOA consistent pharmacodynamic changes in the tumor. This promising data set supports further exploration of DF1001 alone, and in combination with other compounds, as a potential novel therapeutic option for patients with solid tumors.
    Clinical • P1/2 data • Trispecific • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • CD8 (cluster of differentiation 8)
    |
    HER-2 expression
    |
    DF1001
    over1year
    Study of DF1001 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2; N=220 --> 490 | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Apr 2022 --> Jul 2025
    Trial completion date • Trial primary completion date • Enrollment change
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    HER-2 positive • EGFR mutation • HR positive • HER-2 mutation • HER-2 expression • RET mutation • HER-2-H
    |
    HercepTest
    |
    Opdivo (nivolumab) • albumin-bound paclitaxel • DF1001